Jump to content

Talk:Catumaxomab

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

T-lymphocytes

[edit]

Catumaxomab works by linking the T-lymphocytes with the cancer cells. --Blake3522 08:24, 14 July 2007 (UTC)[reply]

Yes. --Blake3522 10:33, 27 July 2007 (UTC)[reply]

No mention of Bispecific

[edit]

Just thought I'd leave a note to say there's no mention of bispecific on this page and its somewhat significant as being the first approved (see bispecific wiki page and also https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784585/). If anyone wants to add it, that'd be great, I'll add it at some point in the future if not (bit busy currently). --TobyBrann 16:02, 13 August 2019 (UTC)[reply]

Fatality in a clinical trial should be mentioned

[edit]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053709/pdf/oncotarget-07-28059.pdf — Preceding unsigned comment added by 69.203.73.17 (talk) 03:03, 1 April 2020 (UTC)[reply]